Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

argenx SE (ARGX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
323.10+7.13 (+2.26%)
At close: 04:00PM EDT
323.75 +0.65 (+0.20%)
After hours: 05:38PM EDT
Advertisement
Sign in to post a message.
  • B
    Brian
    Been in ARGX since Nov of 2017 at $22.50, 15,000 shares. It's always been a solid investment. and now paying off big time. Any other longs here?
  • S
    Sean 007
    $ARGX The U.S. Food and Drug Administration today approved Vyvgart (efgartigimod) for the treatment of generalized myasthenia gravis.
  • S
    Steve
    The call went extremely well. Price is $225,0000 per patient per year. The label is extremely broad and will allow for many other indications. Approval will be granted in Japan China Israel and EU next year.

    Bottom line is the approval could not have gone better. Every key biotech analyst from all the major brokerage houses were on the call at 6:00pm on a Friday night.

    Just spectacular.
  • B
    Benpattan
    ARGX is well over a year ahead of Momenta (and at least six months ahead of UCB) and has an existing collaboration with J&J. I think the answer is that ARGX doesn’t want to be acquired. It suggests that their recently successful test results for efgartigimod might suggest a larger than expected market size now that J&J has expressed interest on it.
  • A
    Aäron
    On my route to work I drive by the company laboratoria at 'industriepark Zwijnaarde'. Each time I call out a blessing so that the stock may rise. You can al thank me here.
  • B
    Benpattan
    Is anyone else on this board? I pointed out the same upward creep in GLPG and looked what happened. similarly, something is pushing ARGX to daily highs. I, of course, possess ‘massive’ buying power, myself, but my best efforts ceased at $100 when J&J jumped aboard. Come on, people, wakey, wakey. Somebody must know something!
  • e
    eddy
    No brainer investment. In since $40
  • B
    Benpattan
    Biotechs in general and ARGX in particular don’t go with market. Often they do best when the mkt is down. ARGX has a history of treading water for weeks, then riveting up or down on no news. Two weeks ago it was up 13 points inter-day and closed up 9 on good volume. Just take a Valium when it’s going against you. Today it’s up 4, again it’s on no news. There will be news later this year, probably the launch of its first potentially blockbuster drug and maybe some feedback on the joint venture with J&J that owns about 8% of the company. Unfortunately, being a Belgian company, hard news can be scarce and this board almost worthless!
  • B
    Benpattan
    Does anyone understand today’s sell off? (It was up 8 PST Monday). I have read the transcript and other than trial delays due to the virus, can see no smoking gun to cause this. Anybody have a clue?
  • B
    Benpattan
    Boy, they really raised that $500 million easily. Wonder if J&J will increase its 8% stake.
  • D
    Dan’y
    argenx Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis
    Regulated Information/Inside Information
    • Independent data monitoring committee confirmed go-forward decision based on evaluation of interim safety as well as efficacy assessments that surpassed pre-defined “GO” threshold
    •  
    • 130 patients targeted for enrollment to support registrational program in CIDP
    •  
    • Management to host conference call today at 2:30 p.m. CET (8:30 a.m. ET)
    February 1, 2021
  • S
    Steve
    Congrats to all longs !!!
  • B
    Benpattan
    Big write-up this week on Seeking Alpha. Nothing new except pointing out that the ‘catalysts’ will be coming next year so we are in limbo for now. Do wish we could get more detail on the blood cancer drug that got $300 million from J&J plus persuaded them to cough up anothr $200 million to buy about 8% of the company. J&J has an existing blockbuster leukaemia drug (shared with ABBV) with sales about $5 billion. Wondering if J&J sees something similar in ARGX’s drug? Very little written on this, emphasis is always concentrated on its major drug that’s due next year.
  • I
    IH8theHeat
    u see big YUGE selling around 3pm BIG YUGE
  • B
    Bioscience NL
    De Europese beurzen diepen door zorgen over de wereldeconomie de verliezen nog uit. 'We zitten al in een berenmarkt', poneert Morgan Stanley. In de Bel20 zijn Solvay en Umicore de grootste dalers.
    De Europese beurzen diepen door zorgen over de wereldeconomie de verliezen nog uit. 'We zitten al in een berenmarkt', poneert Morgan Stanley. In de Bel20 zijn Solvay en Umicore de grootste dalers.
    www.tijd.be
  • g
    gregory s
    anyone know why this is tanking? Big conference on Monday - thought that would be a positive.
  • B
    Bioscience NL
    Nomura/Instinet initiates coverage on argenx SE (NASDAQ: ARGX) with a Buy rating and a price target of $161.00.

    70$ upfront to 161 ,- not bad . Who is selling now ?
  • I
    IH8theHeat
    adrain newland is DENTIST JOKE
  • B
    Bioscience NL
    Top NEWS
    Published: 08:00 CEST 22-08-2018 /GlobeNewswire /Source: argenx SE / : ARGX /ISIN: NL0010832176

    argenx announces that AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-oncology antibody



    Breda, the Netherlands/Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the exercise by AbbVie of its exclusive license option to develop and commercialize ARGX-115, an antibody targeting the novel immuno-oncology target glycoprotein A repetitions predominant (GARP).

    "We are very excited by AbbVie's decision to exercise its option to license and develop ARGX-115, given its compelling track record in oncology. We are proud of the work that this milestone represents for argenx - both in efficiently advancing a premier Innovative Access Program candidate to clinical development and in facilitating wider recognition of the important research out of the de Duve Institute / Université Catholique de Louvain around this first-in-class target," said Tim Van Hauwermeiren, Chief Executive Officer of argenx. "Our Innovative Access Program remains a strategic priority for us, capitalizing on the combined strengths of the argenx antibody platform and the deep disease biology expertise at research institutions. We continue to seek out cutting-edge research and targets while advancing our current collaborations, all with the potential to broaden our pipeline and demonstrate our discipline as a strategic partner."

    "Immuno-oncology is one of AbbVie's key focus areas in our mission to discover and develop medicines that drive transformational improvements in cancer treatment," said Tom Hudson, M.D., Vice President, Oncology Early Discovery and Development, AbbVie. "Our collaboration with argenx over the past two years has been productive, and we look forward to continue working together to fuel scientific progress for patients."

    argenx and AbbVie entered into an option and license agreement for ARGX-115 in April 2016. With the option exercise announced today, AbbVie obtains a worldwide, exclusive license to develop and commercialize ARGX-115-based products. argenx is now eligible to potentially receive development, regulatory and commercial milestone payments of up to $625 million, as well as tiered royalties on ARGX-115-based product sales, if approved. argenx also has the right to co-promote ARGX-115-based products in the EU and Swiss Economic Area.

    About ARGX-115

    ARGX-115 employs argenx's SIMPLE Antibody(TM) technology and binds specifically to the protein glycoprotein A repetitions predominant (GARP), which plays a key role in the regulation of production and release of active transforming growth factor beta (TGF-beta). ARGX-115 is believed to selectively limit the immunosuppressive activity of activated regulatory T-cells (Tregs), thereby stimulating the immune system to attack cancer cells. While the normal function of Tregs is to suppress certain compartments of the immune system to prevent self-directed immune responses through the release of active TGF-beta, Tregs can also prevent the immune system from recognizing and suppressing pathogenic cells including cancer cells. argenx believes the selective inhibition of TGF-beta release by Tregs is potentially superior to systemic inhibition of TGF-beta activity or depletion of Tregs and may give rise to therapeutic products with an improved safety profile.



    ARGX-115 was discovered under argenx's Innovative Access Program with the de Duve Institute / Université Catholique de Louvain / WELBIO and exclusively licensed under a research and option agreement in 2013.



    About the Innovative Access Program (IAP)

    Through the IAP, argenx collaborates closely with academic centers of excellence and emerging biotechnology companies, bringing cutting-edge antibody discovery technologies to the heart of novel target research. The extraordinary diversity of the immune repertoires comprising its SIMPLE Antibody(TM) Platform streamlines target validation, transforming novel protein discoveries into next generation therapeutic antibody programs.

    About argenx

    argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The company is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. argenx's ability to execute on this focus is enabled by its suite of differentiated antibody technologies. The SIMPLE Antibody(TM) Platform, based on the powerful llama immune system, allows argenx to exploit novel and complex targets, and its three complementary Fc engineering technologies
    AbbVie pharmaceuticals combines advanced science with expertise to make strides in drug and treatment discovery, making a remarkable impact on people's lives.
    AbbVie pharmaceuticals combines advanced science with expertise to make strides in drug and treatment discovery, making a remarkable impact on people's lives.
    www.abbvie.com.
Advertisement
Advertisement